Table 1 Cas9 variants that have been modified to broaden the scope of application

From: CRISPR/Cas9 therapeutics: progress and prospects

Variant name

Resources (PAM)

Selection strategy

PAM

Ref.

spCas9-NG

SpCas9 (NGG)

Elimination of the interaction between Cas9 and the third position of PAM

NG

115

xCas9

SpCas9

PACE

NG, GAA, GAT

116

Cas9-NRNH

SpCas9

PANCE and PACE that evolved by enabling SpCas9 to bind to specific sequences with non-G PAMs

NRNH

114

SpG

SpCas9

Structure-guided engineering

NGN

117

SpRY

SpCas9

Structure-guided engineering

Almost unlimited

117

Cas9-VQR

SpCas9

Bacterial selection system

NGAN

NGCG

341

Cas9-EQR

SpCas9

Bacterial selection system

NGAG

341

SaCas9-KKH

SaCas9 (NNGRRT)

Molecular evolution and bacterial selection system

NNNRRT

112

eNme2-C

NmCas9 (NNNNGATT)

PANCE, ePACE, and BE-PPT

Almost unlimited

113

eNme2-C.NR

NmCas9

PANCE, ePACE, and BE-PPT

Almost unlimited

113

eNme2-T.1

NmCas9

PANCE, ePACE, and BE-PPT

NTN

113

eNme2-T.2

NmCas9

PANCE, ePACE, and BE-PPT

NTN

113

  1. N is any nucleotide. R is A or G. H is A, C and T
  2. PACE phage­assisted continuous evolution, PANCE phage-assisted noncontinuous evolution, BE-PPA base-editing-dependent PAM profiling assay, ePACE eVOLVER-enabled20 phage-assisted continuous evolution